Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy in preclinical mouse models.
Engineered bacteria delivered to bladder tumors partner with checkpoint therapy to trigger protective immune memory against cancer.
Probiotic bacteria (E. coli Nissle 1917) were engineered to secrete CXCL13 and delivered intravesically to bladder tumors, where they colonized and induced germinal center formation in tumor-draining lymph nodes, generating tumor-specific antibodies that act as critical partners to PD-1 checkpoint blockade. Combination therapy in two aggressive orthotopic models improved survival and conferred protective immunity upon tumor rechallenge, establishing a synthetic-biology approach to convert immunologically cold tumors via humoral immunity amplification.
What the study was
- Study design
- preclinical experimental
- Population
- orthotopic bladder cancer mouse models (immunologically cold)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Science Translational Medicine
Why it surfaced
First demonstration that intratumoral synthetic-biology bacteria (CXCL13-EcN) can reprogram bladder tumor immunity via humoral mechanisms; directly addresses immune exclusion in bladder cancer and provides a manufacturable, probiotic-based combination immunotherapy strategy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.